Replies to post #184224 on Anavex Life Sciences Corp (AVXL)

[MycroftHolmes]

The findings have the same objective value regardless of where it is published.

But I also did a double-take when I saw the paper was published in Cell.

That would have been an indication that the establishment is embracing this paradigm in a serious way.


Cheers

Mycroft

[Doc328]

Its kind of like the difference between hitting a home run off the local high school pitcher compared to hitting one off of Sandy Koufax in his prime. Both may give a valuable memory but only one would give bragging rights for the rest of your career.

Thousands of labs in the world will get Cell delivered every 2 weeks leading to tremendous multidisciplinary exposure and many citations. Cells is searchable so articles are readily available to those using Pubmed and other engines. Value is of course in the eye of the beholder --- I'm sure most on this board would find an article about A273 more valuable than an article about another drug. In science value is often measured by the citation rate and generally articles in first rate journals are cited more than those in second rate journals.

Theoretically, articles in both are reliable. The vetting process for Cell is more difficult leading to a low acceptance rate. However, both have articles reviewed by 2 experts in the field so articles with major flaws will be excluded.

Does than mean my missing 's' makes the findings about A2-73 less reliable and valuable?